...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: What's the deal with Zenith?

Buckeyes, I think we're all getting lost in the monkey wrench  "Don" threw at us.

Jonzobot said it best over at the Resverlogix Agoracom board:

"Now because he can't find money, he's going to screw up Zenith by selling it's royalties on a gamble to pay for the next RVX trial."

In my opinion, this is all a pipe dream.

I'm surprised we have not heard from KayakerBC on all of this!

 

Koo

 

Share
New Message
Please login to post a reply